RT Journal Article
SR Electronic
T1 Metabolomic analysis of exhaled breath condensate in patients with asthma and COPD
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P3559
VO 42
IS Suppl 57
A1 Paolo Montuschi
A1 Debora Paris
A1 Dominique Melck
A1 Salvatore Valente
A1 Nadia Mores
A1 Andrea Trové
A1 Chiara Mondino
A1 Leonello Fuso
A1 Giuseppe Santini
A1 Francesco Macagno
A1 Matteo Sofia
A1 Andrea Motta
YR 2013
UL http://erj.ersjournals.com/content/42/Suppl_57/P3559.abstract
AB We studied the discriminating capacity of NMR spectroscopy-based metabolomics of exhaled breath condensate (EBC) in asthma and COPD patients, who were either steroid-naive or treated with inhaled corticosteroids (ICS) [fluticasone (500-1000 μg/day) for at least 2 months], and healthy subjects. Twenty-seven steroid-naive COPD patients (21/6, males/females, age 67±2 years, mean±SEM, FEV1 68±2.9% predicted value), 20 COPD patients on ICS (16/4, males/females, age 70±2 years, FEV1 73±4.2% predicyed value), 21 steroid-naive asthmatics (16/5, males/females, age 32±3.9 years, FEV1 99±4.9% predicted value), 19 asthmatics on ICS (14/5, males/females, age 31±4.0 years, FEV1 85±5.0% predicted value), and 15 healthy subjects (8/7, males/females, age 28±1 years, FEV1 116±2.6% predicted value) were included in a cross-sectional study. Asthma and healthy subjects were nonsmokers, COPD patients were exsmokers. EBC was collected after 20 min of tidal breathing (Ecoscreen, Jaeger, Hoechberg, Germany). 1H-NMR spectra (Bruker Avance spectrometer) were data reduced to buckets (AMIX 3.6 package, Bruker Biospin, Rheinstetten, Germany) and normalized to total spectral area. Good reproducibility and no salivary contamination was previously reported (Montuschi P et al, Thorax, 2012). PLS-DA showed all study groups were separated (R2=0.79, Q2=0.80), suggesting an effect of ICS on EBC metabolites which has to be investigated in prospective controlled studies.